Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience. (November 2015)

• Record Type: Journal Article
• Authors: Migliore, Marcello; Calvo, Damiano; Criscione, Alessandra; Palmucci, Stefano; Fuccio Sanzà, Giovanni; Caltabiano, Rosario; Spatola, Corrado; Privitera, Giuseppe; Aiello, Marco Maria; Parra, Hector Soto; Ciancio, Nicola; Di Maria, Giuseppe
• Is Part Of: Future oncology. Volume 11(2015)Supplement 24
• Page Start: 19
• Page End: 22
• Publication Date: 2015-11
• Subjects: chemotherapy -- cisplatin -- cytoreductive surgery -- HITHOC -- hyperthermic perfusion -- mesothelioma -- multimodality treatment -- VATS; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.286
• Languages: English
• ISSNs: 1479-6694

Abstract

Cytoreductive surgery and hyperthermic intraoperative intrapleural chemotherapy (HITHOC) are a known option for malignant pleural mesothelioma (MPM). This prospective study was started to prove that pleurectomy/decortication and HITHOC could be successfully performed in a low volume center. Criteria of inclusion were a proven diagnosis of MPM, early-stage disease and good performance status. Six consecutive patients were enrolled. After pleurectomy/decortication, intrapleural cisplatin was administered for 60 min at 42.5°C. Wedge resections and diaphragmatic reconstruction were added in two and one patient, respectively. Morbidity was 16.6%. Mortality was nil. Hospital stay was 7.8 days. Mean survival was 21.5 months (range: 6–30). This small experience confirms that pleurectomy/decortication and HITHOC are a good therapeutic option in the multimodality treatment of MPM. A randomized controlled trial is necessary.